Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact.

European Journal of Clinical Pharmacology
Zoltán KissJános Szegedi

Abstract

Cloning of the human erythropoietin (EPO) gene and development of the first recombinant human erythropoietin (rHuEPO) drug were truly breakthroughs. This allowed a deeper understanding of the structure and pharmacology of rHuEpo, which in turn inspired the discovery and development of additional erythropoiesis-stimulating agents (ESAs). In vivo specific activity and serum half-life of rHuEPO are influenced by the amount and structure of the attached carbohydrate. Increased numbers of sialic acids on carbohydrate attached to rHuEPO correlated with a relative increase in in-vivo-specific activity and increased serum half-life. The effect of increasing the number of sialic-acid-containing carbohydrates on in-vivo-specific activity was explored. Initial research focused on solving the problem of how the protein backbone could be engineered so a cell would add more carbohydrate to it. Additional work resulted in darbepoetin alfa, a longer-acting molecule with two additional carbohydrate chains.

References

Nov 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·F K LinZ Stabinsky
May 15, 1967·JAMA : the Journal of the American Medical Association·C L FischerC A Berry
Jul 26, 1996·The Journal of Biological Chemistry·B H JiangG L Semenza
Nov 30, 1999·Journal of the American Society of Nephrology : JASN·I C MacdougallJ Egrie
Dec 3, 1999·The International Journal of Biochemistry & Cell Biology·S S Watowich
Apr 20, 2001·British Journal of Cancer·J C Egrie, J K Browne
Jun 13, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·J C Egrie, J K Browne
Jul 2, 2002·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Iain C Macdougall
Nov 12, 2002·Clinical Pharmacology and Therapeutics·Michael AllonBradley J Maroni
Mar 4, 2003·Nature Biotechnology·Steve ElliottJoan Egrie
May 15, 2003·Proceedings of the National Academy of Sciences of the United States of America·Serhat ErbayraktarMichael Brines
Feb 6, 2004·The Journal of Biological Chemistry·Steve ElliottTony Lorenzini
Sep 15, 1951·Experientia·C ARNAUDIR ALLEGRANZA
Dec 14, 2004·Experimental Hematology·Steve ElliottIan Ponting
Apr 14, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Huub Schellekens
May 25, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·John GlaspyUNKNOWN Darbepoetin Alfa 20010162 Study Group
Jun 17, 2005·Journal of Pharmaceutical Sciences·Angus M Sinclair, Steve Elliott
Oct 27, 2005·Blood·Steve ElliottC Glenn Begley
Nov 16, 2005·The Journal of Biological Chemistry·Alec W Gross, Harvey F Lodish
Aug 8, 2006·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Fernando CarreraCandido Ferreira
Jun 8, 2007·Kidney International·C M LogarS J Shankland
Jun 29, 2007·Nephron. Clinical Practice·Clarence P Alfrey, Steven Fishbane
Aug 3, 2007·The Journal of Clinical Investigation·Shilpa M Hattangadi, Harvey F Lodish
Aug 3, 2007·The Journal of Clinical Investigation·Dragan MarinkovicSaghi Ghaffari
Nov 21, 2007·Kidney International. Supplement·P KatavetinM Nangaku
Nov 9, 2007·International Journal of Cancer. Journal International Du Cancer·Magdalena LaugschWolfgang Jelkmann
Apr 25, 2008·Critical Reviews in Oncology/hematology·Wolfgang JelkmannArthur J Sytkowski
Jul 4, 2008·Journal of the National Comprehensive Cancer Network : JNCCN·John A Glaspy
Sep 11, 2008·Journal of Pharmaceutical Sciences·Sungae S ParkBruce A Kerwin
Oct 17, 2008·Experimental Hematology·Steve ElliottIain C Macdougall

❮ Previous
Next ❯

Citations

Oct 12, 2011·Disaster Medicine and Public Health Preparedness·Nicholas DainiakViktor Meineke
Oct 12, 2012·Applied Microbiology and Biotechnology·M Butler, A Meneses-Acosta
Dec 18, 2012·Advances in Therapy·Ashraf Mikhail, Mourad Farouk
Aug 6, 2013·Clinical Pharmacokinetics·Sameer DoshiJuan José Pérez-Ruixo
Sep 26, 2013·Trends in Pharmacological Sciences·Chava Kimchi-SarfatyZuben E Sauna
Jan 25, 2013·The New England Journal of Medicine·Iain C MacdougallUNKNOWN PEARL Study Groups
Aug 9, 2013·CPT: Pharmacometrics & Systems Pharmacology·X Yan, W Krzyzanski
Aug 25, 2011·Current Opinion in Biotechnology·Roland E Kontermann
Sep 5, 2020·Critical Reviews in Microbiology·Vincent De MaesschalckYves Briers
Aug 26, 2016·Glycobiology·Ajit Varki
Nov 16, 2017·Journal of Labelled Compounds & Radiopharmaceuticals·Xiaoqing ZhuangJuan Li
Jan 10, 2012·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Dennis DoleschelWiltrud Lederle

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved